Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Alteration of plasma von Willebrand factor in the treatment of retinal vein occlusion with cystoid macular edema

View ORCID ProfileHiromasa Hirai, Mariko Yamashita, Masanori Matsumoto, Takeyuki Nishiyama, Daishi Wada, Naoko Okabe, Yutaro Mizusawa, Hironobu Jimura, Tetsuo Ueda, View ORCID ProfileNahoko Ogata
doi: https://doi.org/10.1101/2022.02.18.22271170
Hiromasa Hirai
1Department of Ophthalmology, Nara Medical University, Kashihara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hiromasa Hirai
Mariko Yamashita
2Department of Ophthalmology, Nara City Hospital, Nara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masanori Matsumoto
3Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takeyuki Nishiyama
1Department of Ophthalmology, Nara Medical University, Kashihara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daishi Wada
1Department of Ophthalmology, Nara Medical University, Kashihara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naoko Okabe
1Department of Ophthalmology, Nara Medical University, Kashihara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yutaro Mizusawa
1Department of Ophthalmology, Nara Medical University, Kashihara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hironobu Jimura
1Department of Ophthalmology, Nara Medical University, Kashihara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tetsuo Ueda
1Department of Ophthalmology, Nara Medical University, Kashihara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nahoko Ogata
1Department of Ophthalmology, Nara Medical University, Kashihara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nahoko Ogata
  • For correspondence: ogata{at}naramed-u.ac.jp
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Retinal vein occlusion (RVO) is a major retinal disease accompanied by venous thrombosis. Although several studies have proposed an association between venous thrombosis and von Willebrand factor (VWF), the association between RVO and VWF remains unclear. We aimed to investigate the association between RVO and VWF and the alteration of VWF levels under the anti-vascular endothelial growth factor (VEGF) treatment. We enrolled 55 patients with RVO involved cystoid macular edema. They received intravitreal injection of anti-VEGF drugs, either ranibizumab or aflibercept. We examined the clinical data, measured plasma VWF: antigen (VWF: Ag) and plasma a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity (ADAMTS13: AC) and analyzed them to identify variabilities during the treatment. At the baseline there was no significant difference between the RVO group and age-matched controls in both VWF: Ag and ADAMTS13: AC levels but ADAMTS13:AC was significantly lower in central RVO (CRVO) than in branch RVO (BRVO) (P = 0.015). In BRVO, the negative correlation was found between VWF: Ag and central choroidal thickness (CCT) (r = −0.51, P < 0.001). In BRVO after the anti-VEGF treatment, VWF: Ag decreased significantly from 134% at the baseline to 109% at 1 day after (P = 0.002) and to 107% at 1 month after (P = 0.030). In contrast, ADAMTS13: AC showed no significant difference during this period. In BRVO at 1 month after treatment, we found a negative correlation between VWF: Ag and CCT (r = −0.47, P = 0.001). Our findings suggest an association between VWF and CCT in patients with BRVO, thus the measurement of VWF may be useful for evaluating the disease activity and prognosis.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The authors received no specific funding for this work.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Not Applicable

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The medical research ethics committee of Nara Medical University

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Not Applicable

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Not Applicable

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Not Applicable

Footnotes

  • Phone: +81-744-29-8884 (ext.3433), Fax: +81-744-23-8032, Email: hirai-masa{at}naramed-u.ac.jp (H.H.), k158380{at}naramed-u.ac.jp (T.N.), d.wada{at}naramed-u.ac.jp (D.W.), naoko0811{at}naramed-u.ac.jp (Naoko Okabe), urotauyuwasazumi{at}naramed-u.ac.jp (Y.M.), j-hiro{at}naramed-u.ac.jp (H.J.), tueda{at}naramed-u.ac.jp (U.T.)

  • Phone: +81-742-24-1251, Fax: +81-744-22-2478, Email: marko.yamashita{at}gmail.com (M.Y.)

  • Phone: +81-744-22-3051, Fax: +81-744-29-0771, E-mail: mmatsumo{at}naramed-u.ac.jp (M.M.)

Data Availability

The data file is available https://doi.org/10.6084/m9.figshare.19168346

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted February 21, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Alteration of plasma von Willebrand factor in the treatment of retinal vein occlusion with cystoid macular edema
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Alteration of plasma von Willebrand factor in the treatment of retinal vein occlusion with cystoid macular edema
Hiromasa Hirai, Mariko Yamashita, Masanori Matsumoto, Takeyuki Nishiyama, Daishi Wada, Naoko Okabe, Yutaro Mizusawa, Hironobu Jimura, Tetsuo Ueda, Nahoko Ogata
medRxiv 2022.02.18.22271170; doi: https://doi.org/10.1101/2022.02.18.22271170
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Alteration of plasma von Willebrand factor in the treatment of retinal vein occlusion with cystoid macular edema
Hiromasa Hirai, Mariko Yamashita, Masanori Matsumoto, Takeyuki Nishiyama, Daishi Wada, Naoko Okabe, Yutaro Mizusawa, Hironobu Jimura, Tetsuo Ueda, Nahoko Ogata
medRxiv 2022.02.18.22271170; doi: https://doi.org/10.1101/2022.02.18.22271170

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Ophthalmology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)